Premium
Impact of the pretreatment Glasgow prognostic score on treatment tolerance, toxicities, and survival in patients with advanced head and neck cancer undergoing concurrent chemoradiotherapy
Author(s) -
Chang PeiHung,
Yeh KunYun,
Wang ChengHsu,
Chen Eric YenChao,
Yang ShihWei,
Huang JenSeng,
Chou WenChi,
Hsieh Jason ChiaHsun
Publication year - 2017
Publication title -
head and neck
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.012
H-Index - 127
eISSN - 1097-0347
pISSN - 1043-3074
DOI - 10.1002/hed.24853
Subject(s) - medicine , head and neck cancer , chemoradiotherapy , performance status , oncology , stage (stratigraphy) , cancer , surgery , paleontology , biology
Abstract Background The purpose of this study was to evaluate the impact of the pretreatment Glasgow prognostic score on treatment‐related toxicities, tolerance, and survival in patients with advanced head and neck cancers undergoing concurrent chemoradiotherapy (CRT). Methods We retrospectively analyzed and compared the clinical characteristics, toxicities, and survival of 143 patients with stages III, IVA, and IVB head and neck cancer treated with concurrent CRT according to their Glasgow prognostic score between 2007 and 2010. Results The Glasgow prognostic score was correlated with advanced tumor stage and T/N classification. Patients with a higher Glasgow prognostic score were less likely to tolerate concurrent CRT, experienced more weight loss, required tube feeding support more frequently, and had higher percentage of grade ≥3 hematological toxicities, sepsis, and toxic death. Patients with a Glasgow prognostic score of 0 had better overall and recurrence‐free survival than those with a Glasgow prognostic score of 1 or 2. Conclusion Pretreatment Glasgow prognostic score predicts treatment tolerance, toxicity, and survival in patients with advanced head and neck cancer undergoing concurrent CRT.